CAMBRIDGE, Mass. and LEXINGTON, Ky., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Stemgent, Inc., A ReproCELL Group Company (Cambridge, Massachusetts, USA) and Transposagen Biopharmaceuticals Inc. (Lexington, Kentucky, USA) announced they have entered into a partnership agreement enabling the development of genetically engineered induced pluripotent stem cells (iPSC) services for pharmaceutical, biotechnology, academic and government organizations.
The non-exclusive agreement combines Stemgent's industry-recognized expertise in RNA reprogramming with Transposagen's unique genome editing capabilities providing researchers with the convenience of a single point of contact for customer research or disease model systems using patient-specific iPS cells. The newly created service provides customers with a beginning to end solution, starting with Stemgent's expertise in primary cell establishment and iPS cell generation, through genetic manipulation using Transposagen's diverse methods, and ending with a validated cell line that is capable of appropriate differentiation to cardiomyocytes, neurons or hepatocytes.
"Combining the Transposagen Footprint-Free™ gene editing system with Stemgent's RNA reprogramming expertise promises precise and clean stem cell engineering services ideal for research and translational applications," said Jack Crawford, Director of Sales & Marketing at Transposagen.
"We are very excited to be the first stem cell organization to provide customers with the convenience of a single point-of-contact for a beginning-to-end solution, starting with iPS patient specific samples to differentiated cells that this partnership makes possible," commented Joseph S. Gentile, Chief Executive Officer of Stemgent.
About Stemgent (A ReproCELL Group Company)
Stemgent is engaged in working alongside some of the world's leading stem cell scientists in developing innovative technology and application solutions for the advancement of stem cell research. Our mission is to help simplify and support cellular reprogramming research by producing products being designed by leading stem cell researchers worldwide.
For more information, visit www.stemgent.com.
Transposagen is a worldwide leader in genome engineering technologies and services with applications in therapeutics, research & drug discovery, bioproduction, clinical genetic testing and agriculture. Our products and services include the Footprint-FreeTM Gene Editing System, piggyBacTM, NextGENTM CRISPR, XTNTM and RTNTM TALENs, and custom cell lines, stem cells, and animal models. Our unique genome engineering capabilities allow for the creation of nearly any genetic modification in any genome.
For more information, visit www.transposagenbio.com.
CONTACT: For Stemgent Inc. Joseph S. Gentile, CEO Joe.email@example.com 617-245-0026 For Transposagen Biopharmaceuticals Inc. Jack Crawford, Director, Sales and Marketing firstname.lastname@example.org 315-351-9115
Source:Transposagen Biopharmaceuticals, Inc.; Stemgent